Patient-Reported Outcome Measures
Patient-reported outcome measures (PROMs) — standardized questionnaires that capture patients’ own assessments of their symptoms, function, and quality of life — are essential for conditions like ME/CFS where objective biomarkers are unavailable and the primary disease manifestations (fatigue, pain, cognitive dysfunction, PEM) are subjective experiences.
The Slavin 2023 CDE analysis found that existing ME/CFS data collection instruments overemphasize clinician-observed measures (laboratory values, physical examination findings) and underrepresent patient-reported domains — a pattern that systematically biases the evidence base toward what can be measured by a clinician in a clinic visit and away from what patients experience in daily life (Slavin et al. 2023). The activity and participation domains — the ICF (International Classification of Functioning) categories most relevant to patients’ lived experience — were the least represented.
This measurement gap has epistemic consequences. If the instruments used to study ME/CFS do not measure what patients experience, the resulting evidence base will systematically underestimate disease burden and misrepresent treatment effects. A treatment that improves laboratory values but worsens PEM — a pattern patients have reported for graded exercise therapy — will appear beneficial in a data-collection framework biased toward laboratory values. A 2024 public health study of 544 ME/CFS patients in Germany found that patients reported their experiential knowledge being systematically ignored in clinical encounters, and that diagnostic pigeonholing — assigning patients to psychiatric categories without adequate investigation — was a barrier to appropriate assessment (Habermann-Horstmeier and Horstmeier 2024). (Certainty: 0.65 — n=544; German population; qualitative public health study; self-selection sampling limitation.)
Consequence: What gets measured determines what gets treated, what gets funded, and what gets believed. When patients are excluded from instrument design, the instruments measure what clinicians think matters — not what patients experience. The result is a body of research that systematically misunderstands the disease it is studying. Patient participation in PROM development is not a concession to “patient preference” — it is a methodological requirement for measurement validity. Severity applicability: PROMs developed with patient input are more likely to capture severe-disease experiences (e.g., cognitive impairment that prevents questionnaire completion, pain that exceeds existing scale ranges).